Stroke, dementia, and drug delivery

British Journal of Clinical Pharmacology

Volumn 57, Issue 1, 2004, Pages 15-26

  Ford, G A ^a,b   Bryant, C A ^a   Mangoni, A A ^a   Jackson, S H D ^a,c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Ageing; Dementia; Drug delivery; Imaging; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; AMPHETAMINE; ANTITHROMBOCYTIC AGENT; CANDESARTAN; CHOLINESTERASE INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DONEPEZIL; ESTROGEN; FIBRINOLYTIC AGENT; GALANTAMINE; HEPARIN; HEPARINOID; HYDROXYCHLOROQUINE; LEVODOPA; LOBRADIMIL; LOPERAMIDE; LUBELUZOLE; MEMANTINE; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; PAROXETINE; PEPTIDE; PHYSOSTIGMINE; RIVASTIGMINE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; WARFARIN;

AGING; BEHAVIOR DISORDER; BLOOD CLOT LYSIS; BLOOD PRESSURE MONITORING; BRAIN MAPPING; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DRUG APPROVAL; DRUG DELIVERY SYSTEM; HALLUCINATION; HUMAN; HYPERTENSION; HYPOTENSION; MORBIDITY; MORTALITY; MULTIINFARCT DEMENTIA; NEUROIMAGING; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; STROKE;

ANTICHOLESTEREMIC AGENTS; ANTICOAGULANTS; ASPIRIN; CEREBROVASCULAR ACCIDENT; CLINICAL TRIALS; DEMENTIA; FIBRINOLYTIC AGENTS; HUMANS; HYPERTENSION; MAGNETIC RESONANCE IMAGING; NEUROPROTECTIVE AGENTS; PLATELET AGGREGATION INHIBITORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0347319048     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2003.01939.x     Document Type: Review

References (103)

1. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033-41.
2. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002; 324: 71-86.
3. Zivin JA, Fisher M, DeGirolami U, Hemenway CC, Stashak JA. Tissue plasminogen activator reduces neurological damage after cerebral embolism. Science 1985; 230: 1289-92.
4. Wardlaw JM, del Zoppo G, Yamaguchi T. Thrombolysis for acute ischaemic stroke. Cochrane Stroke Group. Cochrane database of systematic reviews, Issue 1, 2002.
5. Cornu C, Boutitie F, Candelise L, et al. Streptokinase in acute ischemic stroke: an individual patient data meta-analysis: The Thrombolysis in Acute Stroke Pooling Project. Stroke 2000; 31: 1555-60.
6. Ford GA, Freemantle N. ECASS-II: intravenous thrombolysis in acute ischaemic stroke. Lancet 1999; 353: 65.
7. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute stroke. N Engl J Med 1995; 333: 1581-7.
8. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with tissue plasminogen activator for acute hemispheric stroke; the European Cooperative Acute Stroke Trial (ECASS). JAMA 1995; 274: 1017-25.
9. Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet 1998; 352: 1245-51.
10. Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3-5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA 1999; 282: 2019-26.
11. Furlan A, Higashida R, Wechsler L, et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA 1999; 282: 2003-11.
12. Albers GW, Bates VE, Clark WM, Bell R, Verro P, Hamilton SA. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA 2000; 283: 1145-50.
13. Tanne D, Bates VE, Verro P, et al. Initial clinical experience with iv tissue plasminogen activator for acute ischaemic stroke: a multicenter survey: the t-PA Stroke Survey Group. Neurology 1999; 53: 424-7.
14. Schenkel J, Weimar C, Knoll T, et al. R1-Systemic thrombolysis in German stroke units. The experience from the German Stroke data bank. J Neurol 2003; 250: 320-4.
15. Katzan IL, Sila CA, Furlan AJ. Community use of intravenous tissue plasminogen activator for acute stroke: results of the brain matters stroke management survey. Stroke 2001; 32: 861-5.
16. Bravata DM, Kim N, Concato J, Krumholz HM, Brass LM. Thrombolysis for acute stroke in routine clinical practice. Arch Intern Med 2002; 162: 1994-2001.
17. Katzan IL, Hammer MD, Furlan AJ, Hixson ED, Nadzam DM. Quality improvement and tissue-type plasminogen activator for acute ischemic stroke: a Cleveland update. Stroke 2003; 34: 799-800.
18. O'Connor RE, McGraw P, Edelsohn L. Thrombolytic therapy for acute ischemic stroke: why the majority of patients remain ineligible for treatment. Ann Emerg Med 1999; 33: 9-14.
19. Harbison J, Hossain O, Jenkinson D, Davis J, Louw SJ, Ford GA. Diagnostic accuracy of stroke referrals from primary care, emergency room physicians and ambulance staff using the Face Arm Speech Test. Stroke 2003; 34: 71-6.
20. Lees KR, Asplund K, Carolei A, et al. Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: a randomised controlled trial. GAIN International Investigators. Lancet 2000; 355: 1949-54.
21. Diener HC, Cortens M, Ford GA, et al. Lubeluzole in acute ischaemic stroke treatment: a double-blind study with an 8 hour inclusion window comparing a 10 mg daily dose of lubeluzole with placebo. Stroke 2000; 31: 2543-51.
22. Muir KW. Heterogeneity of stroke pathophysiology and neuroprotective clinical trial design. Stroke 2002; 33: 1545-50.
23. Stroke Therapy Academic Industry Roundtable II (STAIR-II). Recommendations for clinical trial evaluation of acute stroke therapies. Stroke 2001; 32: 1598-606.
24. Kidwell CS, Saver JL, Mattiello J, et al. Thrombolytic reversal of acute human cerebral ischaemic injury shown by diffusion/perfusion magnetic resonance imaging. Ann Neurol 2000; 47: 462-9.
25. Hoehn M, Nicolay K, Franke C, van der Sanden B. Application of magnetic resonance to animal models of cerebral ischemia. J Magn Reson Imaging 2001; 14: 491-509.
26. Silverman DH, Phelps ME. Application of positron emission tomography for evaluation of metabolism and blood flow in human brain: normal development, aging, dementia and stroke. Mol Genet Metab 2001; 74: 128-38.
27. Harbison J, Massey A, Barnett L, Hodge D, Ford GA. Rapid ambulance protocol for acute stroke. Lancet 1999; 353: 1935.
28. International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischaemic stroke. Lancet 1997; 349: 1569-81.
29. Bath PM, Lindenstrom E, Boysen G, et al. Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial. Lancet 2001; 358: 702-10.
30. Sonde L, Nordstrom M, Nilsson CG, Lokk J, Viitanen M. A double-blind placebo-controlled study of the effects of amphetamine and physiotherapy after stroke. Cerebrovasc Dis 2001; 12: 253-7.
31. Scheidtmann K, Fries W, Muller F, Koenig E. Effect of levodopa in combination with physiotherapy on functional motor recovery after stroke: a prospective, randomised, double-blind study. Lancet 2001; 358: 787-90.
32. Medical Research Council Cognitive Function and Ageing Study. Cognitive function and dementia in six areas of England and Wales. Psychol Med 1998; 28: 319-35.
33. Stevens T, Livingston G, Kitchen G, Manela M, Walker Z, Katona C. Islington study of dementia subtypes in the community. Br J Psychiatry 2002; 180: 270-6.
34. Melzer D, Ely M, Brayne C. Cognitive impairment in elderly people: population based estimate of the future in England, Scotland and Wales. Br Med J 1997; 315: 462.
35. Hofman A, Ott A, Breteler MM, et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet 1997; 349: 151-4.
36. McKeith I, Del Ser T, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000; 356: 2031-6.
37. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA 1997; 277: 813-17.
38. Department of Health. National service framework for older people. London: DoH, 2001.
39. Wolfson C, Wolfson DB, Ashgarian M, et al. A reevaluation of the duration of survival after the onset of dementia. N Engl J Med 2001; 344: 1111-16.
40. Bosanquet N. The socio-economic impact of Alzheimer's disease. Int J Geriatr Psychiatry 2001; 16: 249-53.
41. O'Brien BJ, Goeree R, Hux M, et al. Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada. J Am Geriatr Soc 1999; 47: 570-8.
42. Farcnik K, Persyko MS. Assessment, measures and approaches to easing caregiver burden in Alzheimer's disease. Drugs Aging 2002; 19: 203-15.
43. European Medicine Evaluation Agency (EMEA.) Note for guidance on medicinal products in the treatment of Alzheimer's disease. London: EMEA, 1997.
44. National Institute of Clinical Excellence. Guidance on the use of donepezil, rivastigmine and galantamine for the treatment of Alzheimer's disease. London: NICE, 2001.
45. Birks JS, Melzer D, Beppu H. Donepezil for mild to moderate Alzheimer's disease. Cochrane database of systematic reviews, 2000; 4: CD001190.
46. Matthews HP, Korbey J, Wilkinson DG, Rowden J. Donepezil in Alzheimer's disease: eighteen month results from Southampton Memory Clinic. Int J Geriatr Psychiatry 2000; 15: 713-20.
47. Mohs RC, Doody RS, Morris JC, et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001; 57: 481-8.
48. Maelicke A, Samochocki M, Jostock R, et al. Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease. Biol Psychiatry 2001; 49: 279-88.
49. Spencer CM, Noble S. Rivastigmine. A review of its use in Alzheimer's disease. Drugs Aging 1998; 13: 391-411.
50. Wilkinson DG, Passmore AP, Bullock R, et al. A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer's disease. Int J Clin Pract 2002; 56: 441-6.
51. Auriacornbe S, Pere JJ, Loria-Kanza Y, Vellas B. Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil. Curr Med Res Opin 2002; 18: 129-38.
52. Cummings JL. Cholinesterase inhibitors: a new class of psychotropic compounds. Am J Psychiatry 2000; 157: 4-15.
53. Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E. A 24-week randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 2001; 57: 613-20.
54. Tariot PN, Cummings JL, Katz IR, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. J Am Geriatr Soc 2001; 49: 1590-9.
55. McKeith I, Fairbairn A, Perry R, Thompson P, Perry E. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. Br Med J 1992; 305: 673-8.
56. Erkinjunti T, Kurz A, Gauthier S, Bullock R, Lilienfield S, Damaraju CV. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet 2002; 359: 1283-90.
57. Cacabelos R, Takeda M, Winblad B. The glutamatergic system and neurodegeneration in dementia: preventative strategies in Alzheimer's disease. Int J Geriatr Psychiatry 1999; 14: 3-47.
58. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003; 348: 1333-41.
59. Orgogozo JM, Rigaud AS, Stoffler A, Mobius HJ, Forette F. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke 2002; 33: 1834-9.
60. Van Gool WA, Weinstein HC, Scheltens P, Walstra GJ, Scheltens PK. Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: an 18-month randomised, double-blind, placebo-controlled study. Lancet 2001; 358: 455-60.
61. Mulnard RA, Cotman CW, Kawas C, et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease. JAMA 2000; 283: 1007-15.
62. Howard R, Ballard C, O'Brien J, Burns A. Guidelines for the management of agitation in dementia. Int J Geriatr Psychiatry 2001; 16: 714-7.
63. Street JS, Clark WS, Gannon KS, et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry 2000; 57: 968-76.
64. Cutler NR, Sramek JJ. Review of the next generation of Alzheimer's disease therapeutics: challenges for drug development. Prog Neuropsychopharmacol Biol Psychiatry 2001; 25: 27-57.
65. Gandy S. Molecular basis for anti-amyloid therapy in the prevention and treatment of Alzheimer's disease. Neurobiol Aging 2002; 23: 1009-16.
66. Janus C, Pearson J, McLaurin J, et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 2000; 408: 979-82.
67. Forette F, Seux ML, Staessen JA, et al. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med 2002; 162: 2046-52.
68. Bryant CA, Jackson SH. Functional imaging of the brain in the evaluation of drug response and its application to the study of aging. Drugs Aging 1998; 13: 211-22.
69. Friston KJ, Malizia AL, Wilson S, Cunningham VJ, Jones T, Nutt DJ. Analysis of dynamic radioligand displacement or 'activation' studies. J Cereb Blood Flow Metab 1997; 17: 80-93.
70. Friston KJ, Grasby PM, Bench CJ, et al. Measuring the neuromodulatory effects of drugs in man with positron emission tomography. Neurosci Lett 1992; 141: 106-10.
71. Dolan RJ, Fletcher P, Frith CD, Friston KJ, Frackowiak RS, Grasby PM. Dopaminergic modulation of impaired cognitive activation in the anterior cingulate cortex in schizophrenia. Nature 1995; 378: 180-2.
72. Ogawa S, Lee TM, Nayak AS, Glynn P. Oxygenation-sensitive contrast in magnetic resonance image of rodent brain at high magnetic fields. Magn Reson Med 1990; 14: 68-78.
73. Kwong KK, Belliveau JW, Chesler DA, et al. Dynamic magnetic resonance imaging of human brain activity during primary sensory stimulation. Proc Natl Acad Sci USA 1992; 89: 5675-9.
74. Logothetis NK, Pauls J, Auhath M, Trinath T, Oeltermann A. Neurophysiological investigation of the basis of the fMRI signal. Nature 2001; 412: 150-7.
75. Cabeza R. Cognitive neuroscience of aging: contributions of functional neuroimaging. Scand J Psychol 2001; 42: 277-86.
76. Suzuki Y, Critchley HD, Suckling J, et al. Functional magnetic resonance imaging of odor identification: the effect of aging. J Gerontol A Biol Sci Med Sci 2001; 56: 756-60.
77. D'Esposito M, Zarahn E, Aguirre GK, Rypma B. The effect of normal aging on the coupling of neural activity to the BOLD haemodynamic response. Neuroimage 1999; 10: 6-14.
78. Hesselmann V, Zaro Weber O, Wedekind C, et al. Age related signal decrease in functional magnetic resonance imaging during motor stimulation in humans. Neurosci Lett 2001; 308: 141-4.
79. Johnson SC, Saykin AJ, Baxter LC, et al. The relationship between fMRI activation and cerebral atrophy: comparison of normal ageing and Alzheimer disease. Neuroimage 2000; 11: 179-87.
80. Gollub RL, Breiter HC, Kantor H, et al. Cocaine decreases cortical cerebral blood flow but does not obscure regional activation in functional magnetic resonance imaging in human subjects. J Cereb Blood Flow Metab 1998; 18: 724-34.
81. Bloom AS, Hoffman RG, Fuller SA, Pankiewicz J, Harsch HH, Stein EA. Determination of drug-induced changes in functional MRI signal using a pharmacokinetic model. Hum Brain Mapp 1999; 8: 235-44.
82. Loubinoux I, Pariente J, Boulanouar K, et al. A single dose of the serotonin neurotransmission agonist paroxetine enhances motor output: double blind, placebo-controlled, fMRI study in healthy subjects. Neuroimage 2002; 15: 26-36.
83. Pariente J, Loubinoux I, Carel C, et al. Fluoxetine modulates motor performance and cerebral activation of patients recovering from stroke. Ann Neurol 2001; 50: 718-29.
84. Furey ML, Pietrini P, Haxby JV. Cholinergic enhancement and increased selectivity or perceptual processing during working memory. Science 2000; 290: 2315-9.
85. Bryant CA, Ouldred E, Suckling J, et al. Using FMRI to investigate anticholinesterase therapy in Alzheimer's disease. Neuroimage 1998; 7: S240.
86. Kitamura Y, Shimohama S, Akaike A, Taniguchi T. The parkinsonian models: invertebrates to mammals. Jpn J Pharmacol 2000; 84: 237-43.
87. Knopman D. Pharmacotherapy for Alzheimer's disease. Curr Neurol Neurosci Rep 2001; 1: 428-34.
88. Emerich DF, Snodgrass P, Pink M, Bloom F, Bartus RT. Central analgesic actions of loperamide following transient penetration of the blood brain barrier with Cereport (RMP-7). Brain Res 1998; 801: 259-66.
89. Emerich DF, Snodgrass P, Dean R, et al. Enhanced delivery of carboplatin into brain tumours with intravenous Cereport (RMP-7): dramatic differences and insight gained from dosing parameters. Br J Cancer 1999; 80: 964-70.
90. Emerich DF, Dean RL, Marsh J, et al. Intravenous cereport (RMP-7) enhances delivery of hydrophilic chemotherapeutics and increases survival in rats with metastatic tumors in the brain. Pharm Res 2000; 17: 1212-19.
91. Wu D, Pardridge WM. Central nervous system pharmacologic effect in conscious rats after intravenous injection of a biotinylated vasoactive intestinal peptide analog coupled to a blood-brain barrier drug delivery system. J Pharmacol Exp Ther 1996; 279: 77-83.
92. Bickel U, Yoshikawa T, Pardridge WM. Delivery of peptides and proteins through the blood-brain barrier. Adv Drug Deliv Rev 2001; 46: 247-79.
93. Kang YS, Voigt K, Bickel U. Stability of the disulfide bond in an avidin-biotin linked chimeric peptide during in vivo transcytosis through brain endothelial cells. J Drug Target 2000; 8: 425-34.
94. Albeck DS, Backman C, Veng L, Friden P, Rose GM, Granholm A. Acute application of NGF increases the firing rate of aged rat basal forebrain neurons. Eur J Neurosci 1999; 11: 2291-304.
95. Albeck DS, Hoffer BJ, Quissell D, Sanders LA, Zerbe G, Granholm AC. A non-invasive transport system for GDNF across the blood-brain barrier. Neuroreport 1997; 8: 2293-8.
96. Becker-Hapak M, McAllister SS, Dowdy SF. TAT-mediated protein transduction into mammalian cells. Methods 2001; 24: 247-56.
97. van Ginkel FW, Jackson RJ, Yuki Y, McGhee JR. Cutting edge: the mucosal adjuvant cholera toxin redirects vaccin proteins into olfactory tissues. J Immunol 2000; 165: 4778-82.
98. Dahlin M, Bjork E. Nasal administration of a physostigmine analogue (NXX-066) for Alzheimer's disease to rats. Int J Pharmacol 2001; 212: 267-74.
99. Fehm HL, Perras B, Smolnik R, Kern W, Born J. Manipulating neuropeptidergic pathways in humans: a novel approach to neuropharmacology? Eur J Pharmacol 2000; 405: 43-54.
100. Born J, Lange T, Kern W, McGregor GP, Bickel U, Fehm HL. Sniffing neuropeptides: a transnasal approach to the human brain. Nat Neurosci 2002; 5: 514-16.
101. Ugwoke MI, Verbeke N, Kinget R. The biopharmaceutical aspects of nasal mucoadhesive drug delivery. J Pharm Pharmacol 2001; 53: 3-21.
102. Law SL, Huang KJ, Chou HY. Preparation of desmopressin-containing liposomes for intranasal delivery. J Control Release 2001; 70: 375-82.
103. Dingemanse J, Soubrouillard C, Paris J, Pisano P, Blin O. Pronounced effect of caprylocaproyl macrogolglycerides on nasal absorption of IS-159, a peptide serotonin 1B/1D receptor agonist. Clin Pharmacol Ther 2000; 68: 114-21.